We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

M-CPP and Fenfluramine in Cocaine Addicts - 3

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000314
First Posted: September 21, 1999
Last Update Posted: January 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
VA Office of Research and Development
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.

Condition Intervention Phase
Cocaine-Related Disorders Drug: M-CPP Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Hospitalization, arrests, jail, employment, psychiataric symptoms

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000314


Locations
United States, New York
VA Medical Center
Brooklyn, New York, United States, 11209
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Investigators
Principal Investigator: Laure Buydens-Branchey, M.D. VA Office of Research and Development
  More Information

ClinicalTrials.gov Identifier: NCT00000314     History of Changes
Other Study ID Numbers: NIDA-09468-3
R01-09468-3
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: January 18, 2017
Last Verified: December 2002

Keywords provided by National Institute on Drug Abuse (NIDA):
cocaine dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Fenfluramine
1-(3-chlorophenyl)piperazine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Serotonin Uptake Inhibitors
Serotonin Agents
Serotonin Receptor Agonists